Coronary stenting and inflammation
- PMID: 16399095
- DOI: 10.1016/j.amjcard.2005.09.064
Coronary stenting and inflammation
Abstract
Restenosis after stent implantation is mainly caused by neointimal proliferation through the stent struts. Experimental studies performed in the last decade indicate that inflammatory mechanisms play a key role in the process of neointimal proliferation and restenosis. Coronary stenting is a strong inflammatory stimulus, and the acute local and systemic inflammatory responses to local inflammation produced by coronary stenting are highly individual and predictive of restenosis and event-free survival. The benefit of anti-inflammatory periprocedural therapy, such as with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) and steroids, and long-term follow-up is dependent on the individual's inflammatory status. Measurement of acute-phase reactants, such as C-reactive protein plasma concentration, appears to be important for the identification of subjects at high risk and the development of specific treatment tailored to individual patients.
Similar articles
-
Is inflammation a contributor for coronary stent restenosis?Med Hypotheses. 2007;68(5):945-51. doi: 10.1016/j.mehy.2006.05.069. Epub 2006 Oct 11. Med Hypotheses. 2007. PMID: 17045418
-
Coronary restenotic reduction of drug-eluting stenting may be due to its anti-inflammatory effects.Med Hypotheses. 2007;69(5):1004-9. doi: 10.1016/j.mehy.2007.01.090. Epub 2007 May 11. Med Hypotheses. 2007. PMID: 17499449
-
Prevention of restenosis after stenting: the emerging role of inflammation.Coron Artery Dis. 2004 Sep;15(6):307-11. doi: 10.1097/00019501-200409000-00002. Coron Artery Dis. 2004. PMID: 15346087 Review.
-
Effects of combined treatment with angiotensin II type 1 receptor blocker and statin on stent restenosis.J Cardiovasc Pharmacol. 2009 Feb;53(2):179-86. doi: 10.1097/FJC.0b013e318199f30b. J Cardiovasc Pharmacol. 2009. PMID: 19188828
-
Restenosis following implantation of bare metal coronary stents: pathophysiology and pathways involved in the vascular response to injury.Adv Drug Deliv Rev. 2006 Jun 3;58(3):358-76. doi: 10.1016/j.addr.2006.01.015. Epub 2006 Mar 6. Adv Drug Deliv Rev. 2006. PMID: 16733073 Review.
Cited by
-
The Development of Design and Manufacture Techniques for Bioresorbable Coronary Artery Stents.Micromachines (Basel). 2021 Aug 20;12(8):990. doi: 10.3390/mi12080990. Micromachines (Basel). 2021. PMID: 34442612 Free PMC article. Review.
-
Gallic Acid Inhibits Proliferation and Migration of Smooth Muscle Cells in a Pig In-Stent Restenosis Model.Chonnam Med J. 2024 Jan;60(1):32-39. doi: 10.4068/cmj.2024.60.1.32. Epub 2024 Jan 25. Chonnam Med J. 2024. PMID: 38304132 Free PMC article.
-
Hypercholesterolemia exacerbates in-stent restenosis in rabbits: Studies of the mitigating effect of stent surface modification with a CD47-derived peptide.Atherosclerosis. 2024 Mar;390:117432. doi: 10.1016/j.atherosclerosis.2023.117432. Epub 2023 Dec 24. Atherosclerosis. 2024. PMID: 38241977 Free PMC article.
-
In vivo evaluation of a novel dexamethasone-heparin-double-coated stent for inhibition of artery restenosis and thrombosis.J Mater Sci Mater Med. 2011 Jun;22(6):1615-23. doi: 10.1007/s10856-011-4334-3. Epub 2011 May 10. J Mater Sci Mater Med. 2011. PMID: 21556976
-
The role of monocyte phenotype switching in peri-procedural myocardial injury and its involvement in statin therapy.Med Sci Monit. 2013 Nov 17;19:1006-12. doi: 10.12659/MSM.889661. Med Sci Monit. 2013. PMID: 24241246 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials